Published in final edited form as:

Int J Toxicol. 2015 January ; 34(1): 4–10. doi:10.1177/1091581814565669.

Tenofovir Disoproxil Fumarate: Toxicity, Toxicokinetics, and Toxicogenomics Analysis After 13 Weeks of Oral Administration in Mice

Hanna H. Ng, Howard Stock, Linda Rausch, Deborah Bunin, Abraham Wang, Shirley Brill, Jason Gow, and Jon C. Mirsalis

Biosciences Division, SRI International, Menlo Park, CA, United States.

Abstract

Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir that exhibits activity against human immunodeficiency virus (HIV) and hepatitis B. The goals of this study were to evaluate the molecular mechanism of TDF-induced toxicity in mice after 13 weeks of daily oral administration (50–1000 mg/kg) by correlating transcriptional changes with plasma drug levels and traditional toxicology endpoints. Plasma levels and systemic exposure of tenofovir increased less than dose-proportionally, and were similar on Days 1 and 91. No overt toxicity was observed following the completion of TDF administration. The kidneys of TDF-treated mice were histopathologically normal. This result is consistent with the genomic microarray results, which showed no significant differences in kidney transcriptional levels between TDF-treated animals and controls. In liver, cytomegaly was observed in mice treated with 1000 mg/kg of TDF after 4 and 13 weeks of TDF-treatment, but mice recovered from this effect following cessation of administration. Analysis of liver transcripts on Day 91 reported elevated levels of *Cdkn1a* in TDF-treated animals compared with controls, which may have contributed to the inhibition of liver cell cycle progression.

Keywords

tenofovir disoproxil fumarate; tenofovir; toxicity; toxicokinetics; toxicogenomics; kidney; liver

Introduction

Tenofovir disoproxil fumarate (TDF; Figure 1), a prodrug of tenofovir, has been widely used for long-term treatment of human immunodeficiency virus (HIV) and chronic hepatitis B (CHB) infections in adult patients.^{1,2} Tenofovir is an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate and acts by inhibiting viral reverse-transcriptase.¹ Its favorable pharmacokinetic profile and intracellular drug level in lymphoid tissue allow for a once-daily oral dose regimen.^{3–5} Compared with other HIV treatments, TDF's oral dosing route, more compliant dosing schedule, and reported better-tolerated

Corresponding Author: Hanna H. Ng, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, United States, hanna.ng@SRI.com.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

safety profile have propelled it to become a first-line treatment for HIV.⁶ TDF is also frequently used in combination with other antiretroviral drugs. Tenofovir's primary route of elimination is through the urine, where it is excreted largely via glomerular filtration and proximal tubular secretion.^{7,8}

Tenofovir containing regimens have been associated with infrequent renal adverse events during clinical trials and in post marketing experience.⁹ Nephrotoxicity has been primarily characterized as proximal tubulopathy with rare occurrence of Fanconi syndrome.^{1,10,11} The exact mechanism of tenofovir-induced nephrotoxicity is not clear but is thought to be related to the accumulation of tenofovir in the proximal tubules. Studies have shown that tenofovir is mainly taken up from the blood into proximal tubule cells by human organic anion transporter 1 (hOAT1) at the basolateral membrane.^{12,13} On the other hand, the apical efflux system responsible for transporting tenofovir out into the tubular lumen for excretion is believed to be the multidrug resistance related protein 4 (MRP-4).¹⁴ It was also shown that tenofovir significantly accumulated in the kidney of the *Mrp4* knockout (KO) mice.¹⁵ In regards to hOAT1 involvement, CHO cells expressing high levels of *hOAT1* exhibit greater levels of cytotoxicity following tenofovir exposure compared to cells lacking the transporter.¹⁶

It has been proposed that these elevated tenofovir levels accumulate in the proximal tubule cells, where they interfere with mitochondrial DNA (mtDNA) replication, causing depletion of mtDNA and secondary impairment of its encoded proteins.¹⁷ Furthermore, the direct role of both MRP-4 and OAT1 in transport and efflux of tenofovir in TDF-related renal proximal tubular toxicity was supported by the study conducted by Kohler *et al.*¹⁸ In that study, renal proximal tubular mtDNA abundance was increased in the *MRP-4* KO mice compared with that in the wild type mice following TDF treatment. In contrast, in the TDF-treated *OAT1* KO mice, renal proximal tubular mtDNA abundance remained unchanged, suggesting prevention of TDF toxicity due to loss of tenofovir transport into the proximal tubules. However, Biesecker *et al.* showed that tenofovir did not affect mtDNA content or levels of mitochondrial enzymes in kidney and other tissues.¹⁹

TDF is used as a long-term treatment for HIV and CHB, despite the potential for nephrotoxicity. It is therefore important to better understand the potential mechanisms behind the toxicity associated with TDF. Toxicogenomics uses microarray technology, which provides sensitive and high-throughput data analysis of gene expression in response to treatments, and therefore it can provide valuable insight into mechanisms of toxicity. It may also identify biomarkers of toxicity in response to tenofovir treatment. Microarray toxicogenomic techniques have been used to define potential biomarker gene sets related to nephrotoxicity.²⁰ For example, we have used toxicogenomic techniques to identify genomic changes associated with pentamethylchoromanol-induced hepatotoxicity.²¹ While toxicogenomics is a powerful tool in understanding the potential mechanisms of toxicity, a more complete picture of response to a drug is built when it is combined with the more traditional toxicology endpoints, such as clinical chemistry, toxicokinetics, and histopathology. The objectives of this study were to evaluate the molecular mechanism of TDF-induced toxicity, if any, in female BALB/c mice by correlating gene expression

changes with plasma drug levels and other traditional toxicology endpoints after 13 weeks of treatment.

Material and Methods

Animals

Female BALB/c mice (Harlan, Livermore, CA), 6–8 weeks old, were maintained on Purina Certified Rodent Chow 5002 (Richmond, IN) and purified tap water *ad libitum* in microisolator cages under controlled lighting (12-h light/dark cycle). All animals were housed 3–5 per cage and treated in accordance with a protocol approved by the SRI Institutional Animal Care and Use Committee (IACUC). Studies were conducted in a facility accredited by the Association for Accreditation and Assessment of Laboratory Animal Care International (AAALAC).

Study Design

Groups of mice were treated daily with 10 ml/kg oral gavage (po) administration of TDF (Gilead Sciences, Foster City, CA) for 1, 28, or 91 days, at doses of 50, 500, or 1000 mg/kg. Control mice were administered a similar volume of vehicle, 50 mM trisodium citrate dihydrate (Sigma-Aldrich). Detailed clinical observations were recorded daily for the first week and then weekly thereafter. Body weights were recorded on Day 1, once weekly for the duration of the study, and at necropsy. Standard serum chemistry and hematology parameters were assessed at Days 92 and 119. Plasma drug levels were determined at 0.5, 2, 6, and 24 hr post-dose on Days 1 and 91. Mice (7–15 per group) were sacrificed on Days 2, 29, or 92 (24 hr after their last dose) while 10 mice per group were sacrificed on Day 119 (28 days after their last dose administration). After gross necropsy, organ weights were determined, sections of liver and kidney samples were processed for toxicogenomics assessment, and major organs from mice sacrificed on Days 29, 92, and 119 were processed for histopathology.

Clinical Pathology

Standard methods were used to measure hematology and clinical chemistry parameters from the blood collected from the retro-orbital sinus. Blood from five mice per group were used for clinical chemistry and the remaining animals in the group (n=2–9) were used for hematology evaluation.

The following hematology parameters were measured using an Advia 120 Analyzer (Bayer HealthCare, Tarrytown, NY): hematocrit (HCT), hemoglobin (HGB), red blood cell count (RBC), total white blood cell count (WBC), absolute and relative differential WBC counts, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCC), platelet count (PLC), mean platelet volume (MPV), reticulocyte count (absolute, REA, and percent, RET), and RBC morphology. The following clinical chemistry parameters and urine total protein were measured using a Cobas c-501 Analyzer (Roche Diagnostics, Indianapolis, IN) and standard methods: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), triglycerides (TRI), blood urea nitrogen (BUN), creatinine (CRE), phosphorus (PHO), total

bilirubin (TBI), sodium (SOD), potassium (POT), chloride (CHL), cholesterol (CHO), glucose (GLU), calcium (CAL), total protein (TPR), albumin (ALB), albumin/globulin ratio, and globulin (GLO).

Plasma Concentration of Tenofovir

Blood samples were collected, with ethylenediaminetetraacetic acid (EDTA) as the anticoagulant, from the retro-orbital sinuses of three mice per group per time point. Calibration standards (2.5, 5, 15, 50, 250, 500, 1000, and 2000 ng/ml) were prepared in blank BALB/c mouse plasma, and 50 μ l aliquots were processed in parallel with study samples. A 100 μ l aliquot of 50 ng/ml indinavir (internal standard) in acetonitrile was added to precipitate plasma proteins. After clarifying by centrifugation, the solvent was removed from the supernatants under vacuum, then the dry residues were reconstituted with 50 μ l water containing 0.2% (v/v) formic acid. Samples (10 or 20 μ l volume) were analyzed by LC-MS/MS using a Synergi Polar-RP column eluted with a gradient of 0.2% (v/v) formic acid in water and 0.2% (v/v) formic acid in acetonitrile. Tenofovir and internal standard indinavir were detected by multiple reaction monitoring after electrospray ionization in the positive ion mode, using the following transitions: m/z 288.1 $\rightarrow$ m/z 176.1 for tenofovir and m/z 614.3 $\rightarrow$ m/z 421.2 for indinavir. The peak area of tenofovir was divided by the peak area of indinavir to obtain a peak area ratio (PAR). Calibration standard curves were generated by performing weighted (1/y) linear regression of the PAR versus tenofovir concentration.

Toxicokinetic Analysis

The measured plasma levels of tenofovir were subjected to noncompartmental toxicokinetic (TK) analysis using WinNonlin software version 5.0 (PharSight Corp., Sunnyvale, CA). The following TK parameters were calculated from the plasma concentration versus time data: $C_{\max}$ (maximum drug concentration), $T_{\max}$ (time at which $C_{\max}$ was observed) and AUC_{last} (area under the plasma drug concentration time curve to the last time point).

Histopathology

Microscopic evaluations were performed on the following tissues from all mice tested: right kidney, liver, gross lesions (including tissue masses and abnormal regional lymph nodes), lungs with bronchi, spleen, duodenum, ileum, jejunum, urinary bladder, mesenteric lymph nodes, brain, and heart. Tissues retained in 10% neutral buffered formalin were subsequently embedded into paraffin, cut approximately 5 mm thick, and stained with hematoxylin and eosin. Microscopic examination was performed by a board-certified veterinary pathologist.

Toxicogenomics: Sample Preparation and Gene Expression Analysis

A section (approximately 20–50 mg) of the left kidney and left lobe of the liver from TDF-treated and vehicle control animals (n=7 per group) was collected for microarray analysis. Total RNA was extracted, processed, labeled, and hybridized to GeneChip Mouse Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA) as previously described.²¹ The microarray data was analyzed by using GeneSpring GX 12.6 software (Agilent Technologies). Per-gene normalization was applied across all of the samples of each experiment to normalize the

expression level around the value of 1 (base 2 log transformed to 0). Microarray entities (probesets) were filtered based on their signal intensity so that at least one of the samples had intensity values within the 20 percentile low cutoff and the 100 percentile high cutoff range. The resulting 23,815 and 24,008 probes that qualified (from a total of 28,815 entities on the GeneChip) were selected for subsequent kidney and liver microarray data analysis, respectively.

Statistical Analysis and Software

Mean and standard deviation were calculated for body weight, clinical pathology, and organ weight data at each evaluation interval. Body weights, organ weights, and clinical pathology data were evaluated by one-way analysis of variance (ANOVA), followed by Dunnett's test (if the ANOVA was significant). For clinical pathology data, values for parameters that were not within the detection threshold were excluded from the statistical evaluation. For microarray toxicogenomic analysis, t-test and Benjamini-Hochberg Multiple Testing Correction were used in statistical analysis.

Results

Toxicity Assessment

Clinical Signs—Female BALB/c mice were exposed to 0, 50, 500, or 1000 mg/kg of TDF, once daily via oral gavage, for 1, 28, or 91 days. A sub-set of mice (10/group) were allowed to recover from any signs of toxicity for 28 days (Day 119) after the discontinuation of the treatment. All animals survived until their scheduled sacrifice. A summary of toxicological evaluation following TDF administration in mice is presented in Table 1. Effects in response to the TDF treatment appeared to occur in a dose-dependent manner. In mice treated with either 50 or 500 mg/kg of TDF, 9 out of 35 mice exhibited ruffled fur. In mice treated with 1000 mg/kg, 31 out of 35 mice exhibited ruffled fur. In addition, in the 1000 mg/kg dose group, one mouse exhibited transient incidences of hunched posture, two mice exhibited hypoactivity and two mice exhibited gasping. On Days 36 and 43, significantly lower mean body weights were observed in mice treated with 1000 mg/kg compared with control animals ($p < 0.05$). However, the body weight of the high-dose animals consistently increased over the duration of the study and was comparable with controls for the remainder of the study.

Clinical Pathology—Blood samples were collected from the retro-orbital sinus on Days 29, 92, and 119, to evaluate hematology and clinical chemistry parameters. The most noticeable changes are presented in Table 1. Slight decreases in cholesterol (CHO) and triglyceride (TRI) levels were recorded across all doses on study Days 29 and 92, generally in a dose-dependent fashion, which is most notable (30–48% decreases) in the animals treated with 1000 mg/kg TDF; however, the changes in these parameters were mostly within the normal reference values, and they recovered after discontinuation of treatment. These changes are considered to have no toxicological significance. Slight but statistically significant changes were seen in the hematology parameters following the treatment of TDF. The changes were generally small and within the normal reference range. No differences

between experimental and control animals in clinical pathology parameters were reported at the end of the recovery period.

Necropsy and Histopathology—No gross findings were observed during necropsy. The only microscopic finding considered related to TDF treatment was cytomegaly in the liver of animals given 1000 mg/kg of TDF at necropsy on study Days 29 and 92 (Figure 1). The finding was present minimally or mildly in 7 of 10 and 6 of 15 mice given 1000 mg/kg/day for 28 and 91 days, respectively. This microscopic finding was normalized by the end of the 4-week recovery period, since it was not present in the liver of mice treated with 1000 mg/kg TDF at Day 119 necropsy. Liver cytomegaly was not present in mice given lower doses of tenofovir at 50 or 500 mg/kg/day. No histopathologic changes were identified in the kidneys of any dose group.

Toxicokinetic Analysis

We examined the plasma levels of tenofovir in systemic circulation after oral administration of 0, 50, 500, or 1000 mg/kg. Analysis of the TK parameters (Table 2) revealed that an increase in the dose of TDF resulted in a less than dose-proportional increase in exposure based on $C_{\max}$ and AUC_{last} , with the highest tenofovir exposure observed in the highest dose group tested (6.3 $\mu\text{g/ml}$ and 29.0 $\text{hr}\cdot\mu\text{g/ml}$, respectively) after the last dose administration. $T_{\max}$ was reached 0.5 hr following oral administration of TDF across all dose groups. In addition, no evidence of accumulation was observed between dosing Days 1 and 91 for either $C_{\max}$ or AUC.

Toxicogenomics

To analyze the most predominant genomic changes associated with TDF treatment, we compared the gene expression profile in the kidneys and livers of the mice in the 1000 mg/kg group with that of the vehicle controls on Day 92. Microarray analysis was performed using the Affymetrix GeneChip® Mouse Gene 1.0 ST Array. Little differential change was found in gene expression in the kidneys treated with TDF or the vehicle control. A greater than 1.5-fold change was noted only for four probes (two up-regulated and two down-regulated; Table 3). The changes in the kidney were all less than 2-fold.

Microarray analysis in the liver showed 11 genes with at least a 2-fold transcriptional change in the 1000 mg/kg TDF-treated mice compared with the controls on Day 92. Six genes were up-regulated, while five genes were down-regulated (Tables 4A and 4B). The transcription of *Cdkn1a* gene, cyclin-dependent kinase inhibitor 1A (p21), in the liver of the 1000 mg/kg dose group was 3.7-fold higher than in the control group.

Discussion

Since the majority of HIV and CHB patients will require a prolonged course of therapy, long-term safety is of the utmost importance. In the present study, we applied an integrated approach to study TDF-induced toxicity after 13 weeks of daily treatment by evaluating the compound using standard toxicology endpoints, toxicokinetics and differential gene expression of the liver and kidney.

The recommended oral dosage of TDF in adult patients is 300 mg/day, which is 4.29 mg/kg assuming 70 kg of human body weight. The human equivalent dose for mouse study would be 53 mg/kg, and a 10-fold margin would be 530 mg/kg, which is comparable with the mid dose level in this study. Overall, oral treatment with TDF was well tolerated in mice exposed to 50, 500, or 1000 mg/kg for 91 days. Even though minimal to mild cytomegaly was detected in the liver of mice treated with 1000 mg/kg of TDF on Days 29 and 92, the significance of cytomegaly in liver is not clear, and is thought to represent an adaptive process in response to tenofovir exposure. Cytomegaly was not observed on Day 119 evaluation which indicates recovery following cessation of administration. This finding was not observed for mice treated with 50 or 500 mg/kg/day TDF. In line with the observed cytomegaly, a 3.7-fold increase in *Cdkn1a* transcription was also observed in the 1000 mg/kg dose group from the toxicogenomic data analysis. *Cdkn1a*, cyclin-dependent kinase inhibitor 1A (also known as p21, Cip1), is involved in the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli.^{22,23} The increase of *Cdkn1a* transcription level may have contributed to the inhibition of cell cycle progression at G1, causing cytomegaly in the liver. It was reported by Aravinthan *et al.* that high-level expression of p21 is associated with fibrosis and other adverse liver-related outcomes of non-alcohol-related fatty liver disease.²⁴ The liver cytomegaly observed after treatment with 1000 mg/kg TDF is considered to be of minimal toxicological significance because it has not been reported in clinical use in HIV patients or in toxicology studies in mice, rats and dogs, while TDF related findings in kidney and gastrointestinal tract were reported in ICR CD-1 mice, Sprague Dawley rats and beagle dogs as reported in the FDA Approval Packages (http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-356_Viread.cfm).

Interestingly, no nephrotoxicity was observed in BALB/c mice treated with any dose of TDF for 91 days in the present study. In humans, nephrotoxicity is the most notable organ toxicity, albeit with a low incidence of occurrence, associated with TDF treatment.^{1,8,10} Nephrotoxicity has also been reported pre-clinically in rats. Treatment of rats with an oral dose of 100 mg/kg TDF for 8 weeks induced renal toxicity, as evidenced by increased kidney weights, increased proximal tubule diameters, and enlarged mitochondria with disrupted crystal structure.¹⁷ Moreover, TDF-treated rats had reduced mtDNA compared with controls.¹⁷ In another study, nephrotoxicity was observed after treatment with 600 mg/kg of TDF for 5 weeks in Wistar rats.²⁵ Depletion of the cellular antioxidant was thought to be the cause of oxidative stress and proximal tubule mitochondrial damage.²⁵ This was supported by the protective role of vitamin E in the tenofovir-induced decreases of renal function in Wistar rats.²⁶ However, the renal toxicity observed following TDF treatment is not a universal finding. Biesecker *et al.* evaluated mtDNA content and enzyme activities from the liver, kidney and muscle from the TDF-treated rats, rhesus monkeys and woodchucks, and reported no effect on mtDNA after oral treatment of TDF.¹⁹

In this study, no renal toxicity was observed in the mice treated with 1000 mg/kg for 91 days. A likely explanation is strain and species difference in either metabolism or toxicologic response to tenofovir. BALB/c is an inbred strain with genetic homogeneity, whereas CD-1 is an outbred stock. Numerous drugs have been shown to be metabolized differently by mice and rats.²⁷ In addition, TDF is an ester prodrug of the potent antiviral

tenofovir. Higher esterase activity in the intestine may lead to a decrease in oral absorption of the prodrug TDF. In fact, TDF showed species-dependent degradation (rat>man>pig) in intestinal homogenates, although mouse was not included in the study.²⁸ In the present study, the exposure of TFV after oral administration of TDF showed a less than dose-proportional increase based on C_{max} and AUC. The mouse AUC plasma levels of tenofovir after 1000 mg/kg dose administration were approximately eight times greater than those reported in the literature in healthy volunteers.²⁹

The genomic findings are in alignment with the toxicity data. No significant transcriptional changes were observed in the kidney, and no significant renal toxicity was observed. Moreover, test article-related microscopic cytomegaly noted in the livers of mice treated with 1000 mg/kg of TDF was associated with *Cdkn1a* transcriptional changes in the same dose group in the same organ. Future studies comparing different strains of mice and with other animal species following TDF exposure would help clarify any specific differences in pharmacokinetics and toxicity in animals.

In summary, chronic treatment with TDF up to a dose of 1000 mg/kg for 91 days did not cause any significant renal toxicity in BALB/c mice, which is consistent with no significant changes in gene expression levels in kidney compared with those in the controls. The findings from this study suggest that the BALB/c mouse may not be the most sensitive animal model to assess TDF-induced nephrotoxicity following chronic treatment.

Acknowledgments

Funding and Acknowledgments

This work was supported by NIH/NIAID Contract N01-AI-70043. We would like to thank Gilead Sciences (Foster City, CA) for their generous donation of TDF. We also thank Elizabeth Zuo and Michael Eckart at the Stanford University Protein and Nucleic Acid Biotechnology Facility for hybridization and image scans of Affymetrix microarray GeneChips.

Abbreviations

AUC_{last}	area under the plasma drug concentration time curve to the last time point
CHB	chronic hepatitis B
CHO	cholesterol
C_{max}	maximum drug concentration
HIV	human immunodeficiency virus
hOAT1	human organic anion transporter 1
KO	knockout
MRP-4	multidrug resistance protein 4
mtDNA	mitochondrial DNA
TDF	tenofovir disoproxil fumarate
TK	toxicokinetic

T_{max}	time at which maximum drug concentration is observed
TRI	triglycerides
WBC	total white blood cell count

References

1. Pham PA, Gallant JE. Tenofovir disoproxil fumarate for the treatment of HIV infection. *Expert Opin Drug Metab Toxicol.* 2006; 2(3):459–469. [PubMed: 16863446]
2. Buti M, Homs M. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. *Expert Rev Gastroenterol Hepatol.* 2012; 6(4):413–421. [PubMed: 22928893]
3. Hawkins T, Veikley W, St Claire RL 3rd, et al. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. *J Acquir Immune Defic Syndr.* 2005; 39(4):406–411. [PubMed: 16010161]
4. Durand-Gasselin L, Van Rompay KK, Vela JE, et al. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. *Molecular pharmaceutics.* 2009; 6(4):1145–1151. [PubMed: 19545170]
5. Van Rompay KK, Babusis D, Abbott Z, et al. Compared to subcutaneous tenofovir, oral tenofovir disoproxil fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques. *Antimicrob Agents Chemother.* 2012; 56(9):4980–4984. [PubMed: 22777046]
6. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis.* 2010; 51(5):496–505. [PubMed: 20673002]
7. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. *J Infect Dis.* 2008; 197(1):102–108. [PubMed: 18171292]
8. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity, 2011 update. *AIDS Res Treat.* 2011; 2011 (354908).
9. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. *Aids.* 2007; 21(10):1273–1281. [PubMed: 17545703]
10. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. *Top HIV Med.* 2008; 16(4):122–126. [PubMed: 18838746]
11. Fung J, Seto WK, Lai CL, et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. *Journal of gastroenterology and hepatology.* 2014; 29(3):428–434. [PubMed: 24372662]
12. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. *Nucleosides, nucleotides & nucleic acids.* 2001; 20(4–7):641–648.
13. Uwai Y, Ida H, Tsuji Y, et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). *Pharmaceutical research.* 2007; 24(4):811–815. [PubMed: 17372702]
14. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. *Antimicrob Agents Chemother.* 2006; 50(10):3297–3304. [PubMed: 17005808]
15. Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. *Molecular pharmacology.* 2007; 71(2):619–627. [PubMed: 17110501]
16. Cihlar T, Laflamme G, Fisher R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. *Antimicrob Agents Chemother.* 2009; 53(1):150–156. [PubMed: 19001108]

17. Lebrecht D, Venhoff AC, Kirschner J, et al. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. *J Acquir Immune Defic Syndr*. 2009; 51(3):258–263. [PubMed: 19582894]
18. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. *Laboratory investigation; a journal of technical methods and pathology*. 2011; 91(6):852–858.
19. Biesecker G, Karimi S, Desjardins J, et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. *Antiviral Res*. 2003; 58(3): 217–225. [PubMed: 12767469]
20. Fielden MR, Eynon BP, Natsoulis G, et al. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. *Toxicol Pathol*. 2005; 33(6):675–683. [PubMed: 16239200]
21. Parman T, Bunin DI, Ng HH, et al. Toxicogenomics and metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. *Toxicol Sci*. 2011; 124(2):487–501. [PubMed: 21920950]
22. Romanov VS, Pospelov VA, Pospelova TV. Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. *Biochemistry. Biokhimiia*. 2012; 77(6):575–584. [PubMed: 22817456]
23. Stivala LA, Cazzalini O, Prosperi E. The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs. *Curr Cancer Drug Targets*. 2012; 12(2):85–96. [PubMed: 22165965]
24. Aravinthan A, Scarpini C, Tachtatzis P, et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. *J Hepatol*. 2013; 58(3):549–556. [PubMed: 23142622]
25. Abraham P, Ramamoorthy H, Isaac B. Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney. *Journal of biomedical science*. 2013; 20 (61).
26. Adaramoye OA, Adewumi OM, Adesanoye OA, et al. Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E. *Journal of basic and clinical physiology and pharmacology*. 2012; 23(2):69–75. [PubMed: 22944656]
27. Kramer SD, Testa B. The biochemistry of drug metabolism--an introduction: part 6. Inter-individual factors affecting drug metabolism. *Chem Biodivers*. 2008; 5(12):2465–2578. [PubMed: 19089818]
28. Van Gelder J, Shafiee M, De Clercq E, et al. Species-dependent and site-specific intestinal metabolism of ester prodrugs. *International journal of pharmaceuticals*. 2000; 205(1–2):93–100. [PubMed: 11000545]
29. Droste JA, Verweij-van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. *Antimicrob Agents Chemother*. 2005; 49(2):680–684. [PubMed: 15673751]

Figure 1.
Structure of tenofovir disoproxil fumarate (TDF).

Figure 2.

Histopathology of (A) normal vehicle control liver and (B) liver from mouse treated with 1000 mg/kg TDF. In (A), liver tissue has uniform nuclei and normal amount of cytoplasm. In (B), liver tissue with mild cytomegaly of hepatocytes with larger nuclei containing prominent nucleoli.

Table 1

Overview of toxicology parameters following TDF administration in mice

TDF Dose Level	50 mg/kg	500 mg/kg	1000 mg/kg
Mortality	0	0	0
Clinical Observations			
Ruffled Fur	9 of 35	9 of 35	31 of 35
Hunched Posture	0	0	1 of 35
Hypoactivity	0	0	2 of 35
Gasping	0	0	2 of 35
Body Weight	NE	NE	↓(Days 36 and 43)
Hematology	NE	NE	NE
Clinical Chemistry			
Day 29 and Day 92	↓(CHO, TRI)	↓(CHO, TRI)	↓(CHO, TRI)
Gross Findings	NE	NE	NE
Histopathology			
Liver (Days 29 and 92)	NE	NE	Minimal/Mild Cytomegaly
Kidney	NE	NE	NE

Note: Animals were sacrificed on Days 29 and 92.

NE= No effect with toxicological significance.

↑=Statistically significant increase;

↓=Statistically significant decrease.

Table 2

Tenofovir toxicokinetic (TK) data following 1 or 91 days of exposure

Dose (mg/kg)	Day	$C_{max} \pm S.E.^a$ (ng/ml)	T_{max} (hr)	$AUC_{last} \pm S.E.^a$ (hr•ng/ml)
50	1	875 ± 118	0.5	3984 ± 318
	91	852 ± 163	0.5	3765 ± 206
500	1	6200 ± 877	0.5	22958 ± 1396
	91	5353 ± 1654	0.5	21497 ± 3133
1000	1	7393 ± 559	0.5	27415 ± 3404
	91	6307 ± 694	0.5	28965 ± 1473

^a S.E.=Standard error

Table 3

Genomic changes in kidneys of mice treated with 1000 mg/kg of TDF for 91 days (T-test $p < 0.05$; N=7)

Probeset ID	Gene Symbol	Gene Description	Fold Change	Regulation
10474077	Gm10804	predicted gene 10804	1.65	Up
10494023	Rorc	RAR-related orphan receptor gamma	1.77	Up
10515201	Cyp4b1	cytochrome p450 Family 4, subfamily b, polypeptide 1	1.60	Down
10557058	Polr3e	polymerase (RNA) III (DNA directed) polypeptide E	1.87	Down

Table 4

Genomic changes in livers of mice treated with 1000 mg/kg of TDF for 91 days

A) Down Expressed Genes (T-test, p<0.05; N=7)			
Probset ID	Gene Symbol	Gene Description	Fold Change
10545862	Cml3	camello-like 3	2.08
10539156	Gm15401	predicted gene 15401	2.44
10461728	Gm4952	predicted gene 4952	2.15
10350733	Rgs16	regulator of G-protein signaling 16	2.86
10408557	Serpinb1a	serine (or cyteine) peptidase inhibitor, clad B, member 1a	2.70

B) Upward Expressed Genes (T-test, p<0.05; N=7)			
Probset ID	Gene Symbol	Gene Description	Fold Change
10443463	Cdkn1a	cyclin-dependent kinase inhibitor 1A (P21)	3.70
10599348	Gria3	glutamate receptor, ionotropic, AMPA3 (alpha 3)	3.34
10350146	Phlda3	pleckstrin homology-like domain, family A, member 3	2.41
10401181	Rdh11	retinol dehydrogenase 11	2.09
10564159	Snord116	small nucleolar RNA, C/D box 116 cluster	2.15
10531111	Sult1e1	sulotransferase family 1E, member 1	4.39